Axonics Modulation Revenue and Competitors

Claim your profile



Total Funding

Estimated Revenue & Valuation

  • Axonics Modulation's estimated annual revenue is currently $161.9M per year.(i)
  • Axonics Modulation received $40.1M in venture funding in April 2018.
  • Axonics Modulation's estimated revenue per employee is $266,787
  • Axonics Modulation's total funding is $735.6M.
  • Axonics Modulation's current valuation is $2.5B. (January 2022)

Employee Data

  • Axonics Modulation has 607 Employees.(i)
  • Axonics Modulation grew their employee count by 15% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Axonics Modulation Technologies, Inc is a privately-held medical device company offering the smallest, longest-lived Sacral Neuromodulation System for patients suffering from Urinary and Fecal dysfunction. The Axonics r-SNM System is approved in Europe, Canada and Australia.

keywords:Biotechnology,Cleantech,Healthcare,Medical Devices,Pharmaceuticals,Wind Power


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Axonics Modulation News

2022-04-17 - Sacral Nerve Stimulation Market Size And Forecast | Nuvectra ...

... Size And Forecast | Nuvectra Corporation, Medtronic PLC, NeuroPace Inc, Laborie Inc, Axonics Modulation Technologies Inc., Nevro Corp.,...

2022-04-17 - Sacral Nerve Stimulation (SNS) Devices Market Growth 2022-2029 ...

Sacral Nerve Stimulation (SNS) Devices Market Growth 2022-2029| Key Players – Axonics Modulation Technologies, IntraPace, Inc, Boston Scientific.

2022-03-30 - Stock Upgrades: Axonics Modulation Shows Rising Relative Strength

Axonics Modulation is working on a cup without handle with a 79.91 entry. See if it can break out in heavy trade.

2020-05-11 - Axonics Modulation Technologies raises $130 million via public offering

Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that is commercializing novel implantable rechargeable sacral neuromodulation devices (r-SNM Systems) for the treatment of bladder and bowel dysfunction, ...

2018-10-31 - Axonics raises $120 million via an Initial Public Offering on NASDAQ

Utrecht (The Netherlands), Cambridge (United States) - Axonics Modulation Technologies announced its Initial Public Offering and listing on the NASDAQ exchange. Shares in the IPO are issued to institutional investors in the US and Europe, raising gross proceeds of $120 million, representing one ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Axonics Modulation Funding

DateAmountRoundLead InvestorsReference
2014-03-26$32.6MUndisclosedEdmond de Rothschild Investment PartnersArticle
2015-12-22$38.5MBAdvent Life SciencesArticle
2017-07-06$20.0MCCICA, IncArticle
2018-04-04$40.1MUndisclosedLongitude CapitalArticle